CD274 and small cell lung carcinoma: A phase II clinical trial (NCT04397003) tested a neoantigen DNA vaccine with the programmed death-ligand 1 (PD-L1) inhibitor durvalumab for extensive-stage small cell lung cancer (ES-SCLC).